RESUMO
Serum lactate dehydrogenase iso-enzyme 1 (S-LD-1) was determined in 24 patients with testicular germ cell tumours who died during follow-up. Serum samples were obtained at the start of chemotherapy or late into the clinical course for those without evidence of a tumour. Seven of the eight patients with tumour-associated death had S-LD-1 > 150 U l-1 (median 260 U l-1 range 90-905 U l-1, as did two of the six who died without evidence of a tumour (median 134 U l-1 range 89-128 U l-1) (P = 0.03, Mann-Whitney U-test, two-tailed). The remaining 10 patients had previously been reported as to prediction of S-LD-1 for the prognosis, and were evaluated only as to the reproducibility of the S-LD-1 determination. S-LD-1 was determined in two serum samples obtained concomitantly from eight of these 10 patients: the difference between the two S-LD-1 determinations was median 6% of the average of the two S-LD-1 determinations (25-75% range 3-17%). Our study showed an unforeseeable high level of imprecision of the assay system. Nevertheless, S-LD-1 determinations in the regular monitoring of patients with testicular germ cell tumours may be useful for predicting tumour-associated deaths.
Assuntos
L-Lactato Desidrogenase/sangue , Neoplasias Embrionárias de Células Germinativas/enzimologia , Neoplasias Testiculares/enzimologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Humanos , Isoenzimas , Masculino , Pessoa de Meia-Idade , Neoplasias Embrionárias de Células Germinativas/mortalidade , Prognóstico , Neoplasias Testiculares/mortalidadeAssuntos
L-Lactato Desidrogenase/sangue , Neoplasias Embrionárias de Células Germinativas/enzimologia , Neoplasias Testiculares/enzimologia , Biomarcadores/sangue , Aberrações Cromossômicas/genética , Transtornos Cromossômicos , Cromossomos Humanos Par 12 , Eritrócitos/enzimologia , Hemólise , Humanos , Isoenzimas , Masculino , Seminoma/fisiopatologiaRESUMO
The present study aimed to evaluate serum lactate dehydrogenase isoenzyme 1 (S-LD-1) as an indicator of relapse for patients with testicular germ cell tumors. Twenty-seven patients were investigated with repeated determinations of S-LD-1 from diagnosis to relapse; 9 had seminoma and 18 nonseminomatous tumors. Eleven of 21 had raised S-LD-1 at relapse (4 with seminoma). Seven of the 27 patients had a raised S-LD-1 for median 2 months (1.4-4.5 months) before relapse was detected. Thus, S-LD-1 is of use, complementary to clinical examinations, determinations of serum alpha fetoprotein and human chorionic gonadotropin, and CT scans, in monitoring patients with testicular germ cell tumors for relapse.
Assuntos
L-Lactato Desidrogenase/sangue , Recidiva Local de Neoplasia/diagnóstico , Neoplasias Embrionárias de Células Germinativas/patologia , Seminoma/patologia , Neoplasias Testiculares/patologia , Adolescente , Adulto , Idoso , Biomarcadores Tumorais/sangue , Ensaios Enzimáticos Clínicos , Humanos , Isoenzimas , Masculino , Pessoa de Meia-Idade , Neoplasias Embrionárias de Células Germinativas/enzimologia , Seminoma/enzimologia , Neoplasias Testiculares/enzimologia , Fatores de TempoRESUMO
Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of 130 mg/m2 every fifth week. No patient had previously received cytotoxic therapy. Among 37 evaluable patients, 26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of 16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was 26 weeks for responders. The treatment schedule was well tolerated with a median dose of 88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas.
